Neuropsychiatry Conferences | Europe | Asia | Middle East | Canada | Japan | Australia | USA

Neuropsychiatry

Neuropsychiatry is an integral part of medicine and science which deals with mental disorders related to the nervous system. Neuropsychiatry is to study neurology and psychiatry in an integrated form. Neuropsychiatry is growing far from other fields of psychiatry and it is also interconnected with behavioral neurology and neuropsychology.

Neuropsychiatry helps the neuroscience field and is helping to give a better understanding of the psychiatry and neurological disorders in order to treat them in a far better way.

Neuropsychiatrists are the physician who has clinical experience and experience in psychiatry with knowledge of neurological disorders. Neuropsychiatrists primarily treat patients suffering from brain malfunctions. Neuropsychiatrists treats these condition with the help of some tools: functional magnetic resonance tomography (fMRI), clinical neurogenetics, magnetic resonance angiography, neuroimaging, electroencephalography, and neural network theory.

Neuropsychiatry addresses these various conditions under it: patients of Parkinson's with delusion and hallucinations, obsessive-compulsive disorder, schizophrenia, and other conditions as well.

Sub-tracks:

Psychiatric genetics
Psycho-oncology
Mind/brain monism
Psychiatric epidemiology
Cultural and religious considerations
Mental well-being and mental illness

Market Analysis: Psychiatric and neurological illnesses are becoming increasingly prevalent in society, owing to rising prevalence of these disorders in adolescents and children, as well as changing demographics. Neuropsychiatric illnesses are the leading cause of decreased quality of life and decreased ability to perform. Neuropsychiatric illnesses are responsible for more than 42% of years spent with a disability in Europe. During the anticipated period, the Neuropsychiatric Disorders and Treatment Market is expected to develop at a CAGR of 6.2 percent. The global market for neuropsychiatric drugs was valued at US$ 14,448.6 million in 2019, with a compound annual growth rate (CAGR) of 4.2 percent from 2019 to 2030. Neuropsychiatric disorders are the most common among those over 65. Some of the important factors driving the growth of the neuropsychiatric medicines market are the rising prevalence of neuropsychiatric illnesses globally and the rising desire for better treatment.

Tracks